1589917612572_5ec429193ef97e0004f1060c_logo.png
Timber Pharmaceuticals Receives Decision to Grant Japanese Patent for Lead Asset TMB-001
April 28, 2021 08:00 ET | Timber Pharmaceuticals
- Company is evaluating a topical pharmaceutical composition of isotretinoin for the treatment of moderate to severe subtypes of congenital ichthyosis - Basking Ridge, NJ, April 28, 2021 ...
1589917612572_5ec429193ef97e0004f1060c_logo.png
Timber Pharmaceuticals Announces Appointment of John Koconis as Chairman of the Board of Directors
April 23, 2021 08:00 ET | Timber Pharmaceuticals
- Edward J. Sitar appointed as Lead Independent Director of the Board - - Company establishes Science and Technology Committee to be chaired by Dr. David Cohen - Basking Ridge, NJ, April 23,...
1589917612572_5ec429193ef97e0004f1060c_logo.png
Timber Pharmaceuticals Sets Record Date for Annual Meeting of Shareholders and Provides Update on Its Annual Filings
April 02, 2021 16:05 ET | Timber Pharmaceuticals
Basking Ridge, NJ, April 02, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. (NYSE American: TMBR) ("Timber” or the "Company"), a biopharmaceutical company focused on the...
1589917612572_5ec429193ef97e0004f1060c_logo.png
Timber Pharmaceuticals Provides Business Update and Announces Year End 2020 Financial Results
March 23, 2021 16:05 ET | Timber Pharmaceuticals
50% of patients in the Phase 2b CONTROL study have now been randomized despite COVID-19 disruptions in the trial marketplace Cash Position of $10.4 Million at December 31, 2020  BASKING RIDGE, NJ,...
1589917612572_5ec429193ef97e0004f1060c_logo.png
Timber Pharmaceuticals’ Development Partner, AFT Pharmaceuticals, Enters into Licensing Agreement for Pascomer® (TMB-002) in Europe
March 17, 2021 08:00 ET | Timber Pharmaceuticals
- Extension of agreement with AFT Pharmaceuticals grants Desitin Arzneimittel GmbH exclusive license and supply rights for TMB-002 in Europe - Basking Ridge, N.J., March 17, 2021 (GLOBE...
1589917612572_5ec429193ef97e0004f1060c_logo.png
Timber Pharmaceuticals Announces 50% Enrollment in Phase 2b CONTROL Study in Congenital Ichthyosis
March 15, 2021 08:30 ET | Timber Pharmaceuticals
- Study is Evaluating TMB-001 (Topical Isotretinoin) in Subtypes of Rare Genetic Keratinization Disorder  - Company Awarded Final Tranche of $1.5 Million FDA Orphan Products Clinical Trials...
1589917612572_5ec429193ef97e0004f1060c_logo.png
Timber Pharmaceuticals Announces Presentation at 2021 H.C. Wainwright Global Life Sciences Conference
March 05, 2021 08:30 ET | Timber Pharmaceuticals
WOODCLIFF LAKE, N.J., March 05, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on...
1589917612572_5ec429193ef97e0004f1060c_logo.png
Timber Pharmaceuticals Appoints Alan Mendelsohn, M.D., as Chief Medical Officer
January 25, 2021 16:05 ET | Timber Pharmaceuticals
Dr. Mendelsohn has 20+ Years’ Experience in Clinical Development and Medical Affairs WOODCLIFF LAKE, NJ, Jan. 25, 2021 (GLOBE NEWSWIRE) --   via NewMediaWire -- Timber Pharmaceuticals, Inc....
1589917612572_5ec429193ef97e0004f1060c_logo.png
Timber Pharmaceuticals Receives Orphan Drug Designation from U.S. FDA for TMB-003 for the Treatment of Systemic Sclerosis
January 12, 2021 16:22 ET | Timber Pharmaceuticals
Timber Expects to Submit Investigational New Drug (IND) Application to the FDA in 2022 WOODCLIFF LAKE, N.J., Jan. 12, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc....
1589917612572_5ec429193ef97e0004f1060c_logo.png
Timber Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for Lead Asset TMB-001
December 15, 2020 08:00 ET | Timber Pharmaceuticals
- Formal notice confirms intent to grant patent for pharmaceutical isotretinoin composition - WOODCLIFF LAKE, N.J., Dec. 15, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals,...